Assuming all options for BCMA-directed therapy are available, how would you approach treatment for a patient with 4 prior lines of myeloma-directed therapy who is eligible for a BCMA-directed therapy?  

Ide-cel? Cilta-cel? Teclistamab?



Answer from: Medical Oncologist at Academic Institution